A Phase 2 interventional study of Pegylated Interferon (PEG-IFN) alfa-2a and Placebo in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 5 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-08-22.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 54th largest by enrollment, is one of 10 that started in 2007, is one of 10 in phase 2, and was the 78th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 10 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 41st largest by enrollment of the 59 interventional ones that give a count, is one of 9 that started in 2007, is one of 16 in phase 2, and was the 80th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1. Participants were randomized to 1 of 3 treatment groups to receive placebo, ribavirin monotherapy 1000 milligrams (mg) to 1200 mg orally daily depending on body weight or pegylated interferon (PEG-IFN) alfa-2a (Pegasys®) 180 micrograms (mcg) subcutaneously (SC) weekly, for 6 weeks. Following the initial 6 weeks, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin (Copegus®) for 12 weeks. If there was an initial virological response after 12 weeks of combination therapy, treatment could be continued for a further 36 weeks outside of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
Drug: Pegylated Interferon (PEG-IFN) alfa-2a · Drug: Ribavirin
Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
Drug: Pegylated Interferon (PEG-IFN) alfa-2a · Drug: Placebo · Drug: Ribavirin
Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
Drug: Pegylated Interferon (PEG-IFN) alfa-2a · Drug: Ribavirin
Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Also known as: Pegasys®
Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Also known as: Copegus®
Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action
To investigate possible action mechanisms, three different models were fitted to viruskinetic data and evaluated using related log-likelihood function values. These models were designed assuming individual effects with respect to infectiousness (model 1), virus production (model 2) or degradation of infected cells rate (model 3). The following viruskinetic parameters were fitted in each model: initial viral load, loss rate of infected cells (delta), effectivity of interferon with respect to a pharmacokinetic-pharmacodynamic model. A lower log likelihood function value indicates a lesser fit for the model.
Time frame: Up to Day 126
Score in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire
SF-36 is a psychometric scale to quantify health conditions. This psychometric scale has 8 dimensions of the subjective health status and consists of 36 individual items that have a varying number of related item scores (ranging from "yes/no" up to a 6-point scale). At first the raw scores were determined by summation over all items and weighted accordingly. Afterwards the raw scores were transformed to ranges of 0-100 with 100 being the highest level of health and compared to published reference scales. The following eight dimensions of subjective health conditions were considered: physical functioning index, role physical index, pain, general health perception, vitality, social functioning index, role emotional index and mental health index. The SF36 questionnaire had to be answered by the patients at screening before monotherapy, after monotherapy and at the end of the study (=end of combination therapy).
Time frame: At screening (Days -56 to -1), at end of monotherapy (Week 6) and at end of combination therapy (Week 18)
Percentage of Participants With Treatment Response
HCV-RNA level was measured at each visit by a central laboratory. Treatment response was estimated applying the following definitions of response/non-response: 1) Adequate first phase decline: HCV RNA decline ≥ 0.5 log10 International Units/milliliter (IU/mL) from time 0 to 48 hours of PEG-IFN treatment (PEG-IFN arm: day 0 - day 2; placebo and ribavirin arm: day 42-day 44), 2) Rapid virologic response: HCV RNA \< 15 IU/mL (=detection limit) on day 70, 3) Complete early virologic response: HCV RNA \< 15 IU/mL on day 126, 4) Partial early virologic response (log decrease): HCV RNA decrease ≥ 2 log10 IU/mL from day 0 to day 126, 5) Partial early virologic response (cut off): HCV RNA \<30000 IU/mL on day 126, 6) Non-response: HCV RNA decrease \<2 log10 IU/mL from day 0 to day 126, 7) Null-response: HCV RNA decrease \<1 log10 IU/mL from day 0 to day 28 and from day 0 to day 70 for PEG-IFN arm and placebo / ribavirin arm, respectively.
Time frame: Up to Day 126
Area Under the Concentration-Time Curve (AUC) of Ribavirin
Evaluation of ribavirin arm after Day 0. Evaluation of placebo and PEG-IFN arms after Day 42.
Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Maximum Concentration (Cmax) of Ribavirin
Cmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.
Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Time to Maximum Concentration (Tmax) of Ribavirin
Tmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.
Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Area Under the Concentration-Time Curve (AUC) of PEG-IFN
Evaluation of PEG-IFN arm after Day 0. Evaluation of ribavirin and placebo arms after Day 42.
Time frame: From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Maximum Concentration (Cmax) of PEG-IFN
Cmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.
Time frame: From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Time to Maximum Concentration (Tmax) of PEG-IFN
Tmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.
Time frame: From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)
Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Maximum Concentration (Cmax) of GPT
Cmax was obtained directly from the concentration-time data.
Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Time to Maximum Concentration (Tmax) of GPT
Tmax was obtained directly from the concentration-time data.
Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
| Milestone | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Started | 14 | 26 | 27 |
| Completed | 14 | 25 | 26 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Milestone | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Started | 14 | 25 | 26 |
| Completed | 14 | 23 | 25 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 2 | 1 |
To investigate possible action mechanisms, three different models were fitted to viruskinetic data and evaluated using related log-likelihood function values. These models were designed assuming individual effects with respect to infectiousness (model 1), virus production (model 2) or degradation of infected cells rate (model 3). The following viruskinetic parameters were fitted in each model: initial viral load, loss rate of infected cells (delta), effectivity of interferon with respect to a pharmacokinetic-pharmacodynamic model. A lower log likelihood function value indicates a lesser fit for the model.
| log likelihood function value | Pegylated Interferon (PEG-IFN) Alfa-2a | Ribavirin | Total Participant Group |
|---|---|---|---|
| Model 1= infectiousness | -27.0 (-34.5 to -14.0) | -21.4 (-24.7 to -15.2) | -22.2 (-26.0 to -19.3) |
| Model 2= virus production | -28.2 (-35.0 to -14.3) | -23.8 (-27.5 to -21.6) | -23.9 (-27.4 to -21.6) |
| Model 3= degradation rate | -27.1 (-33.2 to -14.0) | -20.7 (-25.5 to -16.0) | -23.1 (-26.5 to -18.4) |
SF-36 is a psychometric scale to quantify health conditions. This psychometric scale has 8 dimensions of the subjective health status and consists of 36 individual items that have a varying number of related item scores (ranging from "yes/no" up to a 6-point scale). At first the raw scores were determined by summation over all items and weighted accordingly. Afterwards the raw scores were transformed to ranges of 0-100 with 100 being the highest level of health and compared to published reference scales. The following eight dimensions of subjective health conditions were considered: physical functioning index, role physical index, pain, general health perception, vitality, social functioning index, role emotional index and mental health index. The SF36 questionnaire had to be answered by the patients at screening before monotherapy, after monotherapy and at the end of the study (=end of combination therapy).
| units on a scale | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Physical functioning index: Screening | 95.6 ± 5.2 | 76.5 ± 20.2 | 79.7 ± 28.7 |
| Physical functioning index: End of monotherapy | 90.8 ± 9.2 | 72.3 ± 28.1 | 68.4 ± 27.7 |
| Physical functioning index: End of comb. therapy | 67.1 ± 20.7 | 73.0 ± 14.0 | 53.4 ± 31.5 |
| Role physical index: Screening | 75.0 ± 41.8 | 55.6 ± 41.0 | 62.5 ± 40.8 |
| Role physical index: End of monotherapy | 66.7 ± 34.2 | 56.8 ± 43.4 | 50.5 ± 40.5 |
| Role physical index: End of combination therapy | 25.0 ± 38.7 | 40.0 ± 35.7 | 29.7 ± 40.0 |
| Pain: Screening | 89.3 ± 17.0 | 70.3 ± 26.8 | 70.0 ± 30.8 |
| Pain: End of monotherapy | 73.2 ± 23.3 | 61.5 ± 27.4 | 66.0 ± 29.6 |
| Pain: End of combination therapy | 72.3 ± 32.2 | 56.0 ± 11.8 | 60.1 ± 34.8 |
| General health perception: Screening | 58.6 ± 12.9 | 53.6 ± 14.5 | 62.9 ± 14.5 |
| General health perception: End of monotherapy | 58.2 ± 7.6 | 59.2 ± 16.9 | 54.3 ± 18.0 |
| General health perception: End of comb. therapy | 60.0 ± 14.3 | 55.2 ± 15.0 | 47.1 ± 20.6 |
| Vitality: Screening | 54.2 ± 9.2 | 52.8 ± 21.5 | 50.9 ± 18.9 |
| Vitality: End of monotherapy | 45.0 ± 15.2 | 44.1 ± 16.3 | 41.8 ± 20.1 |
| Vitality: End of combination therapy | 40.8 ± 14.6 | 32.5 ± 12.1 | 39.8 ± 16.1 |
| Social functioning index: Screening | 75.0 ± 23.7 | 79.2 ± 24.2 | 83.8 ± 20.6 |
| Social functioning index: End of monotherapy | 72.9 ± 22.9 | 68.2 ± 24.0 | 80.1 ± 22.6 |
| Social functioning index: End of comb. therapy | 68.8 ± 23.4 | 61.3 ± 19.9 | 56.3 ± 25.8 |
| Role emotional index: Screening | 55.6 ± 50.2 | 66.7 ± 50.0 | 62.5 ± 43.7 |
| Role emotional index: End of monotherapy | 55.6 ± 50.2 | 69.7 ± 45.8 | 53.3 ± 51.6 |
| Role emotional index: End of combination therapy | 33.3 ± 51.6 | 50.0 ± 42.3 | 35.4 ± 39.4 |
| Mental health index: Screening | 68.5 ± 9.1 | 63.1 ± 18.1 | 64.5 ± 15.4 |
| Mental health index: End of monotherapy | 61.3 ± 12.3 | 62.8 ± 14.0 | 61.5 ± 19.7 |
| Mental health index: End of combination therapy | 72.2 ± 9.0 | 61.6 ± 13.2 | 47.7 ± 23.0 |
HCV-RNA level was measured at each visit by a central laboratory. Treatment response was estimated applying the following definitions of response/non-response: 1) Adequate first phase decline: HCV RNA decline ≥ 0.5 log10 International Units/milliliter (IU/mL) from time 0 to 48 hours of PEG-IFN treatment (PEG-IFN arm: day 0 - day 2; placebo and ribavirin arm: day 42-day 44), 2) Rapid virologic response: HCV RNA \< 15 IU/mL (=detection limit) on day 70, 3) Complete early virologic response: HCV RNA \< 15 IU/mL on day 126, 4) Partial early virologic response (log decrease): HCV RNA decrease ≥ 2 log10 IU/mL from day 0 to day 126, 5) Partial early virologic response (cut off): HCV RNA \<30000 IU/mL on day 126, 6) Non-response: HCV RNA decrease \<2 log10 IU/mL from day 0 to day 126, 7) Null-response: HCV RNA decrease \<1 log10 IU/mL from day 0 to day 28 and from day 0 to day 70 for PEG-IFN arm and placebo / ribavirin arm, respectively.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Adequate first phase decline | 79 | 65 | 72 |
| Rapid virologic response | 43 | 30 | 20 |
| Complete early virologic response | 64 | 48 | 72 |
| Partial early virologic response (log decrease) | 79 | 78 | 84 |
| Partial early virologic response (cut off) | 79 | 78 | 84 |
| Non-response | 21 | 22 | 16 |
| Null responder | 36 | 26 | 12 |
Evaluation of ribavirin arm after Day 0. Evaluation of placebo and PEG-IFN arms after Day 42.
| (microgram/milliliter)*day ([mcg/ml]*d) | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) of Ribavirin | 186.6 (142.3 to 201.4) | 179.4 (142.6 to 203.8) | 290.1 (257.6 to 370.5) |
Cmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.
| mcg/ml | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Maximum Concentration (Cmax) of Ribavirin | 2.95 (2.79 to 3.60) | 2.83 (2.34 to 3.26) | 3.37 (2.93 to 4.19) |
Tmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.
| weeks | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Ribavirin | 6.0 (4.0 to 12.0) | 8.0 (6.0 to 12.0) | 6.4 (6.1 to 8.0) |
Evaluation of PEG-IFN arm after Day 0. Evaluation of ribavirin and placebo arms after Day 42.
| (nanogram/milliliter)*day ([ng/ml]*d) | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) of PEG-IFN | 2097.9 (1763.5 to 2997.3) | 1270.4 (931.8 to 1572.0) | 1164.9 (925.2 to 1461.3) |
Cmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.
| ng/ml | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Maximum Concentration (Cmax) of PEG-IFN | 28.77 (22.80 to 32.38) | 20.36 (16.92 to 25.83) | 19.8 (15.80 to 22.30) |
Tmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.
| weeks | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of PEG-IFN | 6.3 (6.1 to 8.0) | 12.0 (6.0 to 12.0) | 6.0 (6.0 to 12.0) |
| (Units/liter)*day ([U/L]*d) | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT) | 5078.3 (4358.3 to 6576.5) | 7233.5 (5337.3 to 8656.3) | 5231.3 (3917.0 to 5852.5) |
Cmax was obtained directly from the concentration-time data.
| U/L | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Maximum Concentration (Cmax) of GPT | 68.5 (59.0 to 112.0) | 88.0 (67.0 to 123.0) | 75.0 (56.0 to 110.0) |
Tmax was obtained directly from the concentration-time data.
| days | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of GPT | 2.8 (2.0 to 28.0) | 14.0 (10.0 to 42.5) | 3.0 (2.0 to 7.0) |
Collected over Up to Day 126. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN Alfa-2a, Period 1 Monotherapy | — | 0/14 (0%) | 9/14 (64.3%) |
| Placebo, Period 1 Monotherapy | — | 1/26 (3.8%) | 9/26 (34.6%) |
| Ribavirin, Period 1 Monotherapy | — | 0/27 (0%) | 12/27 (44.4%) |
| PEG-IFN Alfa-2a, Period 2 Combination Therapy | — | 0/14 (0%) | 12/14 (85.7%) |
| Placebo, Period 2 Combination Therapy | — | 2/25 (8%) | 23/25 (92%) |
| Ribavirin, Period 2 Combination Therapy | — | 2/26 (7.7%) | 24/26 (92.3%) |
| Event | PEG-IFN Alfa-2a, Period 1 Monotherapy | Placebo, Period 1 Monotherapy | Ribavirin, Period 1 Monotherapy | PEG-IFN Alfa-2a, Period 2 Combination Therapy | Placebo, Period 2 Combination Therapy | Ribavirin, Period 2 Combination Therapy |
|---|---|---|---|---|---|---|
| DepressionPsychiatric disorders | 0/14 | 1/26 | 0/27 | 0/14 | 1/25 | 0/26 |
| Retinal haemorrhageEye disorders | 0/14 | 0/26 | 0/27 | 0/14 | 1/25 | 0/26 |
| Otitis mediaInfections and infestations | 0/14 | 0/26 | 0/27 | 0/14 | 0/25 | 1/26 |
| Urinary tract infectionInfections and infestations | 0/14 | 0/26 | 0/27 | 0/14 | 0/25 | 1/26 |
| PsychotherapySurgical and medical procedures | 0/14 | 0/26 | 0/27 | 0/14 | 0/25 | 1/26 |
| Event | PEG-IFN Alfa-2a, Period 1 Monotherapy | Placebo, Period 1 Monotherapy | Ribavirin, Period 1 Monotherapy | PEG-IFN Alfa-2a, Period 2 Combination Therapy | Placebo, Period 2 Combination Therapy | Ribavirin, Period 2 Combination Therapy |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/14 | 4/26 | 4/27 | 2/14 | 10/25 | 5/26 |
| FatigueGeneral disorders | 3/14 | 1/26 | 4/27 | 0/14 | 9/25 | 6/26 |
| Influenza like illnessGeneral disorders | 3/14 | 0/26 | 0/27 | 1/14 | 5/25 | 9/26 |
| NauseaGastrointestinal disorders | 2/14 | 2/26 | 1/27 | 4/14 | 8/25 | 5/26 |
| DiarrhoeaGastrointestinal disorders | 1/14 | 0/26 | 1/27 | 0/14 | 5/25 | 1/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/14 | 0/26 | 0/27 | 0/14 | 5/25 | 2/26 |
| PruritusSkin and subcutaneous tissue disorders | 0/14 | 0/26 | 0/27 | 1/14 | 5/25 | 4/26 |
| DizzinessNervous system disorders | 0/14 | 0/26 | 0/27 | 0/14 | 2/25 | 5/26 |
| Decreased appetiteMetabolism and nutrition disorders | 1/14 | 0/26 | 1/27 | 0/14 | 4/25 | 3/26 |
| Sleep disorderPsychiatric disorders | 0/14 | 1/26 | 2/27 | 0/14 | 4/25 | 2/26 |
| Age, Continuous(years) | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin | Total |
|---|---|---|---|---|
| Mean | 45.8 ± 14.4 | 48.2 ± 15.4 | 50.2 ± 12.9 | 48.5 ± 14.1 |
| Sex: Female, Male(Participants) | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin | Total |
|---|---|---|---|---|
| Female | 7 | 18 | 17 | 42 |
| Male | 7 | 8 | 10 | 25 |
The record gives a start of Apr 2007, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin